Journal
JOURNAL OF VIROLOGICAL METHODS
Volume 235, Issue -, Pages 92-98Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jviromet.2016.05.016
Keywords
Hepatitis B core-related antigen; Pathological grade; Pathological stage; Noninvasive diagnosis
Funding
- 12th Five-year National Science and Technology Key Projects of China [2013ZX10002005]
- Key scientific research project of Shanghai municipal health and Family Planning Commission of China [20134032]
Ask authors/readers for more resources
The objective of this study was to evaluate the validities of serum hepatitis B core-related antigen (HBcrAg) for predicting the pathological status of liver tissues of chronic hepatitis B (CHB). A total of 205 Chinese patients with CHB, including 121 HBeAg-positive and 84 HBeAg-negative patients, were enrolled in this study. In HBeAg-positive patients, AUCs of serum HBcrAg for predicting severe necro-inflammation and advanced fibrosis were greater than 0.70; using serum HBcrAg < = 4.81 x 10(4) kU mL(-1) and < = 2.45 x 10(4) kU mL(-1) as cutoffs, the sensitivities, specificities, accuracies for predicting severe necro-inflammation and advanced fbrosis were 0.697, 0.716, 0.711 and 0.818, 0.778, 0.785, respectively. In HBeAg-negative patients, the ADCs of serum HBcrAg for predicting significant necro-inflammation and significant fibrosis were greater than 0.70; using serum HBcrAg > = 1.70 x 10(2) kU mL(-1) and > = 4.02 kU mL(-1) as cutoffs, the sensitivities, specificities, accuracies for predicting significant necro-inflammation and significant fibrosis were 0.929, 0.964, 0.952 and 1.000, 1.000, 1.000, respectively. These results indicated favorable performances of serum HBcrAg for predicting severe necro-inflammation and advanced fibrosis in HBeAg-positive patients and significant necro-inflammation and significant fibrosis in negative patients. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available